Mirati Therapeutics, Inc. Profile Avatar - Palmy Investing

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
Major Shareholders · Outstanding & Floating · Short Interest

Share Analysis

Breakdown
Mirati Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.
Short
Fail To Deliver
Not available for MRTX
Shorts Over Time
Not available for MRTX
Latest Settlement
Settlement Date n/a
Short Volume $n/a
Change n/a
Short Float n/a
Change n/a
Days to Cover n/a
Change n/a